The tweet was deleted by the author.
But we saved everything 🙂.
CVRx has announced its preliminary first-quarter 2026 financial results, projecting revenue between 14.7 million and 14.8 million dollars and indicating approximately 20 percent growth compared to the same period of 2025.
The company also noted that early data in 2026 is showing encouraging trends, signaling continued momentum as CVRx advances its financial performance into the year. Further details on full-year guidance and other metrics were not disclosed in this initial update.
Earlier in 2026, CVRx presented data at ACC26 showing its Barostim device therapy improved exercise capacity for heart failure patients beyond standard GDMT in a clinical update. Previously, the company backed the first Barostim implant at Ascension Alexian Brothers, making the new device therapy available for heart failure treatment in a hospital setting. These initiatives have marked recent milestones for CVRx as it expands its Barostim platform.